| Objective To evaluate the clinical value of 99mTc-octreotide somatostatin receptorscintigraphy and SPECT/CT fusion technique for the diagnosis of the lung cancer.Methods Forty three consecutive patients with pulmonary neoplasm which weredivided into two groups of lung cancer and benign one, including 36 lung cancer and7 lung benign neoplasm were studied. Planar imaging was obtained after injection of99mTc-octreotide 740～1110MBq at 15min,1h,3h, SPECT/CT fusion imagings wereperformed at 2～3h post injection. All scintigraphically detected lesions wereconfirmed by histopathological analysis after imaging. The sensitivity,specificity andaccuracy of image fusion,planar image and CT were obtained..Tumor to normaltissues ratios (T/NT) were observed using ROI(region of interest). The difference ofT/NT in different lung cancer.Results The sensitivity, specificity and accuracy of 99mTc-octreotide SPECT/CTfusion imaging in detection of lung cancer were 94.4%,85.7%,93.0%, respectively.Those of planar image is 77.8%, 85.7%,76.7%. Those of CT image is 77.8%, 57.1%,74.4%,respectively. There was significant difference between 7 case of pre-chemotherapy SCLC with average value of T/NT 3.36±0.50 and 24 cases of NSCLC withaverage value of T/NT 2.12±0.57(t=5.184, P＜0.01). There was aslo significantdifference between pre-chemotherapy whose average value of T/NT is 3.36±0.50 andpost-chemotherapy whose average value of T/NT is 2.06±0.38((t=3.325, P＜0.01).Conclusion 99mTc-octreotide SPECT/CT fusion imaging has a good value fordetection of the primary tumor of lung cancer.Its sensitivity and accuracy issignificant higher than that of CT image. It is also used to distinguish the SCLC fromNSCLC. With the capability of predicting the cytoactive of lung cancer cell andchemo- therapy effect of SCLC. |
PDF Full Text Request